SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from Mosaic ImmunoEngineering Inc. (CPMV) (CIK 0000836564) (CPMV) — Jan 25, 2021

Mosaic ImmunoEngineering Inc. (CPMV) (CIK 0000836564)
Date: Jan. 25, 2021 · CIK: 0000836564 · Accession: 0001683168-21-000250

AI Filing Summary & Sentiment

File numbers found in text: 333-251261

Date
January 25, 2021
Author
Not clearly detected
Form
CORRESP
Company
Mosaic ImmunoEngineering Inc. (CPMV) (CIK 0000836564)

Letter

VIA EDGAR Division of Corporation Finance Office of Life Sciences Washington, DC 20549 Re: Mosaic ImmunoEngineering Inc. Amendment No. 1 to Registration Statement on Form S-3/A File No. 333-251261

Dear Messrs. Gessert and Buchmiller:

Mosaic ImmunoEngineering Inc. (the “Company”) hereby requests that the effectiveness of the above-referenced registration statement on Form S-3/A be accelerated so that it will become effective at 4:00 p.m. Eastern time on January 29, 2021, or as soon thereafter as practicable.

This letter constitutes the Company’s confirmation of its awareness of its obligations under the Act.

Please telephone the undersigned at (657) 208-0890 or Dean Colucci of Duane Morris LLP at (973) 424-2020 if you have any questions with respect to the foregoing.

Very truly yours,
Mosaic ImmunoEngineering Inc.

Show Raw Text
CORRESP
1
filename1.htm

January 25, 2021

VIA EDGAR

Mr. David Gessert

Mr. Tim Buchmiller

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, DC 20549

    Re:
    Mosaic ImmunoEngineering Inc.

    Amendment No. 1 to Registration Statement on Form S-3/A

    File No. 333-251261

Dear Messrs. Gessert and Buchmiller:

Mosaic ImmunoEngineering
Inc. (the “Company”) hereby requests that the effectiveness of the above-referenced registration statement on Form
S-3/A be accelerated so that it will become effective at 4:00 p.m. Eastern time on January 29, 2021, or as soon thereafter as practicable.

This letter constitutes
the Company’s confirmation of its awareness of its obligations under the Act.

Please telephone the
undersigned at (657) 208-0890 or Dean Colucci of Duane Morris LLP at (973) 424-2020 if you have any questions with respect to the
foregoing.

        Very truly yours,

        Mosaic ImmunoEngineering Inc.

    By:
    /s/ Steven King

    Name:
    Steven King

    Title:
    President and Chief Executive Officer

cc:

Dean M. Colucci, Esq.

Duane Morris LLP

1537
S. Novato Blvd, Novato CA 94947

www.mosaicie.com
| info@mosaicie.com